Pharmacogenomics Technology
A Global Strategic Business Report
MCP32564
WHAT'S BEHIND OUR DATA?
140857226
DOMAIN TRANSCRIPTS6080276
BRANDS TRACKED1729341
FEATURED COMPANIES22574
TOPICS COVERED82719
MARKET SEGMENTS91
KEY INDUSTRIES1574
CURATION TEAM4761909
DECISION MAKERSEXECUTIVE ENGAGEMENTS BY TIER (55)
3
CXO5
VICE PRESIDENT10
DIRECTOR25
MANAGER12
MARKETING
REQUEST FULL-STACK INDEX
Includes 350+ pages validated sources
QUESTIONNAIRE
EXECUTIVES
DATA ROOM
HIGHLIGHTS & REPORT INDEX
Global Pharmacogenomics Technology Market to Reach US$11.4 Billion by 2030
The global market for Pharmacogenomics Technology estimated at US$7.1 Billion in the year 2024, is expected to reach US$11.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Neurological Disorders segment is estimated at 8.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 12.9% CAGR
The Pharmacogenomics Technology market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
Pharmacogenomics Technology Market: Key Trends & Drivers Summarized
How Is Pharmacogenomics Transforming Drug Development and Personalized Medicine?
Pharmacogenomics technology is revolutionizing the pharmaceutical industry by enabling personalized medicine based on an individual’s genetic makeup. By studying how genetic variations influence drug response, pharmacogenomics allows for the development of targeted therapies, optimized drug dosages, and reduced adverse reactions. This shift from a one-size-fits-all approach to precision medicine enhances treatment efficacy and minimizes trial-and-error prescribing, significantly improving patient outcomes.
Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) are increasingly recognizing pharmacogenomics in drug approvals, labeling, and post-market surveillance. Many pharmaceutical companies are integrating pharmacogenomic data into clinical trials to identify biomarkers, stratify patient populations, and accelerate drug development timelines. With the rapid advancement of next-generation sequencing (NGS), CRISPR-based gene editing, and artificial intelligence (AI)-powered genetic analysis, pharmacogenomics is poised to become a cornerstone of precision medicine.
What Are the Key Trends Driving the Growth of Pharmacogenomics Technology?
The field of pharmacogenomics is evolving rapidly, driven by breakthroughs in genomic sequencing, bioinformatics, and AI-driven drug discovery. One of the most significant trends is the widespread adoption of whole-genome sequencing (WGS) and next-generation sequencing (NGS), which enable rapid and cost-effective identification of genetic variants linked to drug metabolism. With the decreasing cost of sequencing technologies, pharmacogenomics testing is becoming more accessible for clinical applications and population-wide studies.
Another key trend is the integration of AI and machine learning (ML) in pharmacogenomics research. AI-powered algorithms can analyze vast amounts of genetic data to identify drug-gene interactions, predict treatment responses, and develop personalized drug regimens. AI-driven drug discovery platforms are also accelerating the identification of novel biomarkers and therapeutic targets, reducing the time and cost associated with traditional drug development.
The rise of direct-to-consumer (DTC) pharmacogenomics testing is another transformative trend. Companies like 23andMe and Color Genomics are offering genetic testing kits that provide consumers with insights into their drug metabolism and potential adverse drug reactions. While regulatory oversight remains a challenge, the increasing demand for consumer-driven healthcare is fueling the growth of this market.
Furthermore, CRISPR-based gene editing and gene therapy advancements are expanding the scope of pharmacogenomics beyond diagnostics into therapeutic applications. Gene-editing technologies are enabling customized drug development, targeted cancer therapies, and rare disease treatments, further propelling the demand for pharmacogenomics-driven precision medicine.
How Are End-Use Applications Shaping the Pharmacogenomics Market?
Pharmacogenomics technology is influencing multiple therapeutic areas, including oncology, cardiology, psychiatry, neurology, and infectious diseases. Each segment benefits from pharmacogenomics in unique ways, optimizing drug selection and treatment strategies.
Oncology is one of the most significant areas where pharmacogenomics is making an impact. Targeted cancer therapies such as HER2 inhibitors for breast cancer (trastuzumab) and EGFR inhibitors for lung cancer (gefitinib) are based on genetic profiling. Pharmacogenomic testing helps oncologists determine which patients will benefit most from specific treatments, reducing toxicity and improving survival rates. The rise of companion diagnostics, which pair genetic testing with specific cancer drugs, is further driving growth in this sector.
In cardiology, pharmacogenomics is being used to tailor treatments for hypertension, anticoagulation, and cholesterol management. Genetic testing can predict how patients metabolize clopidogrel (Plavix), warfarin, and statins, ensuring that they receive the most effective and safest dosage. This reduces the risk of adverse drug reactions (ADRs) and thrombotic complications, improving cardiovascular disease management.
Psychiatry and neurology are also experiencing significant advancements due to pharmacogenomics. Antidepressants, antipsychotics, and epilepsy medications often exhibit high variability in patient response. Genetic testing helps predict how individuals metabolize drugs such as SSRIs, lithium, and carbamazepine, reducing treatment resistance and side effects. Pharmacogenomics is also playing a role in Alzheimer’s and Parkinson’s disease research, helping to identify potential therapeutic targets based on genetic risk factors.
In the infectious disease sector, pharmacogenomics is being applied to antiviral therapies, antibiotic resistance studies, and vaccine development. For example, genetic testing can determine how patients respond to HIV treatments like abacavir (HLA-B*5701 screening) or hepatitis C therapies, improving antiviral efficacy and reducing hypersensitivity reactions.
Additionally, pharmacogenomics is playing a crucial role in rare disease drug development and orphan drug approvals. Many genetic disorders require highly targeted therapies, and pharmacogenomics is enabling the identification of gene-based treatment strategies for conditions like cystic fibrosis, sickle cell disease, and Duchenne muscular dystrophy.
What Factors Are Driving the Growth of the Pharmacogenomics Technology Market?
The growth in the pharmacogenomics technology market is driven by several factors, including advancements in genomic sequencing, increasing demand for personalized medicine, regulatory support, and expanding applications in drug development. As healthcare shifts toward precision medicine, pharmaceutical companies, research institutions, and healthcare providers are investing heavily in genetic testing, bioinformatics platforms, and AI-driven drug discovery tools.
One of the primary growth drivers is the decreasing cost of genetic sequencing. The cost of whole-genome sequencing has dropped significantly, making pharmacogenomics testing more accessible and cost-effective. As a result, healthcare providers are incorporating genetic profiling into routine clinical practice, expanding the market for pharmacogenomics-based diagnostics and therapeutics.
Regulatory agencies are also playing a key role in promoting pharmacogenomics. The FDA has issued pharmacogenomic labeling for over 300 drugs, highlighting genetic markers that influence drug metabolism and efficacy. Additionally, initiatives such as the All of Us Research Program (U.S.) and the UK Biobank Project are collecting large-scale genetic data to advance pharmacogenomics research, fueling further adoption of the technology.
The increasing prevalence of chronic diseases, cancer, and drug-resistant infections is also driving demand for pharmacogenomics solutions. As traditional treatment approaches often result in variable drug responses and adverse reactions, pharmacogenomics provides a solution by enabling precision prescribing and individualized treatment strategies. Furthermore, pharmaceutical companies are leveraging pharmacogenomics to optimize clinical trials and accelerate drug development. By stratifying patient populations based on genetic profiles, companies can improve trial success rates, reduce drug development costs, and bring therapies to market faster. The rise of companion diagnostics and biomarker-driven drug approvals is further strengthening the link between pharmacogenomics and pharmaceutical innovation.
Additionally, government funding and public-private partnerships are fueling research and commercialization efforts. Organizations such as the National Institutes of Health (NIH), the European Medicines Agency (EMA), and the Japan Agency for Medical Research and Development (AMED) are investing in pharmacogenomics research, enabling breakthroughs in gene-based therapy development and population-wide genetic screening initiatives. As pharmacogenomics continues to integrate with AI, big data, and precision drug discovery, the field is poised for exponential growth, transforming the way drugs are developed, prescribed, and monitored. With advancements in gene sequencing, biomarker identification, and AI-driven analysis, pharmacogenomics will play an increasingly central role in shaping the future of personalized medicine and precision healthcare.
SCOPE OF STUDY
The report analyzes the Pharmacogenomics Technology market by the following Segments, and Geographic Regions/Countries:
Segments:
Therapeutic Area (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases); Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..
SELECT PLAYERS
23andMe, Inc.; Abbott Laboratories; Agilent Technologies, Inc.; Becton, Dickinson and Company; bioMérieux S.A.; Bio-Rad Laboratories, Inc.; Coriell Life Sciences; Eurofins Scientific; F. Hoffmann-La Roche Ltd; Genomind, Inc.; Guardant Health, Inc.; Illumina, Inc.; Merck KGaA; Myriad Genetics, Inc.; Pacific Biosciences of California, Inc.; Pathway Genomics Corporation; PerkinElmer, Inc.; QIAGEN N.V.; Thermo Fisher Scientific Inc.; Wellness Labs
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy |
| How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind |
| Pharmacogenomics Technology – Global Key Competitors Percentage Market Share in 2025 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2025 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Rising Demand for Personalized Medicine Drives Adoption of Pharmacogenomics in Drug Development and Clinical Practice |
| Expansion of Precision Oncology and Targeted Therapeutics Strengthens Business Case for Pharmacogenomic Testing |
| Increasing FDA and EMA Support for Companion Diagnostics Accelerates Integration of Pharmacogenomics into Drug Labeling |
| Technological Advancements in Next-Generation Sequencing (NGS) and Microarray Platforms Enhance Genotyping Efficiency |
| Growing Pipeline of Biomarker-Driven Therapies Spurs Demand for High-Throughput Pharmacogenomics Solutions |
| Expansion of Pharmacogenomics Panels Beyond Oncology Supports Broader Application in Cardiology, Psychiatry, and Pain Management |
| Integration of AI and Bioinformatics in Genomic Data Interpretation Strengthens Clinical Utility and Decision Support |
| Rising Adoption of Pharmacogenomic Testing in Primary Care and Retail Clinics Expands Market Accessibility |
| Value-Based Healthcare and Outcome-Driven Models Promote Reimbursement for Pharmacogenomics-Guided Therapy |
| Growth in Direct-to-Consumer Genetic Testing Encourages Awareness and Uptake of Pharmacogenomics in Wellness and Preventive Care |
| Increased Regulatory Emphasis on Drug Safety and Adverse Event Reduction Drives Investment in Genomic Risk Screening |
| Integration of Pharmacogenomic Data into Electronic Health Records (EHRs) Enhances Workflow and Clinical Adoption |
| Expansion of Clinical Trials Incorporating Genotype Stratification Supports Personalized Drug Response Analysis |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Pharmacogenomics Technology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030 |
| World Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Pharmacogenomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for In-situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for In-situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for In-situ Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| USA Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| JAPAN |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| CHINA |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| EUROPE |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Pharmacogenomics Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| FRANCE |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| GERMANY |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| UNITED KINGDOM |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| UK Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Spain 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Spain Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Spain 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Russia 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Russia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Russia 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| ASIA-PACIFIC |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Pharmacogenomics Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| AUSTRALIA |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E) |
| Australia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Australia 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Australia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Australia 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| INDIA |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E) |
| India Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| India 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| India Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| India 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| South Korea 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| South Korea Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| South Korea 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| LATIN AMERICA |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E) |
| Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Pharmacogenomics Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Latin America 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Latin America 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Latin America 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Argentina 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Argentina Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Argentina 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Brazil 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Brazil Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Brazil 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Mexico 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Mexico Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Mexico 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Latin America 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Rest of Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Latin America 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| MIDDLE EAST |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E) |
| Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Pharmacogenomics Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Middle East 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Middle East 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Middle East 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Iran 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Iran Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Iran 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Israel 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Israel Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Israel 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Saudi Arabia 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Saudi Arabia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Saudi Arabia 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| UAE 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| UAE Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| UAE 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Middle East 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Rest of Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Rest of Middle East 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
| AFRICA |
| Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E) |
| Africa Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Africa 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030 |
| Africa Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR |
| Africa 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030 |
COMPETITIVE METRICS
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]